OXFORD, United Kingdom, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference, 9 February 2016 at 11:00am EST in New York City.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit | Tel: +44 (0)1235 443 951 +1 617 225 4455 | ||||
Cairn Financial Advisers LLP |
Tel: +44 (0)20 77148 7900 | ||||
N+1 Singer
|
Tel: +44 (0)20 7496 3000 | ||||
Peckwater PR
| Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk | ||||
| MacDougall Biomedical Communications (US media contact) Chris Erdman | Tel: +1 781 235 3060 cerdman@macbiocom.com | ||||
-END-
